Browsing Tag
Tenaya Therapeutics
5 posts
Can RNA interference expand beyond rare diseases through Tenaya–Alnylam cardiovascular research? (NASDAQ: ALNY, NASDAQ: TNYA)
Tenaya Therapeutics and Alnylam Pharmaceuticals partner to discover RNAi drug targets for cardiovascular disease. Read what this biotech deal could mean.
Is gene therapy ready for the heart? TN-201’s pause raises doubts
Find out why the FDA paused Tenaya’s gene therapy for heart disease and what it means for biotech's future in cardiac gene delivery.
Tenaya Therapeutics’ TN-201 gene therapy shows early success in treating MYBPC3 hypertrophic cardiomyopathy
Discover how Tenaya Therapeutics’ TN-201 gene therapy is showing early signs of transforming treatment for MYBPC3-associated HCM—read more on the trial details and outlook.
Gene therapy dreams on hold? Inside the FDA move that rattled Tenaya Therapeutics
Find out why the FDA paused Tenaya’s TN-201 trial for heart disease and what this could mean for gene therapy investors and the company’s future.
Tenaya Therapeutics’ TN-201 demonstrates tolerability and protein expression in early HCM trial
Tenaya Therapeutics, a clinical-stage biotechnology company, has released promising interim results from its MyPEAK-1 Phase 1b/2 clinical trial…